Ashley Gallagher, Associate Editor

Artificial intelligence could help detect a trend in medical information for individuals that would help physicians predict an increased risk of sudden cardiac death.

The approval makes enzalutamide the first and only androgen receptor-signaling inhibitor approved for the treatment of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastatic.

Capivasertib is indicated for hormone receptor-positive, human epidermal growth factor 2-negative locally advanced or metastatic breast cancer with 1 or more PIK3CA/ALT1/PTEN-alterations.

In human heart tissues, investigators found that the mechanism associated with heart failure can be reversed and Dicer activity can be restored when AD-9308 was used.

Repotrectinib is a tyrosine kinase inhibitor (TKI) that targets ROS1 and is administered as an oral therapy for treatment of locally advanced or metastatic ROS1-positive non–small cell lung cancer.

Taurolidine and heparin (Defencath; CorMedix) is indicated to reduce catheter-related bloodstream infections for adults with kidney failure who are receiving chronic hemodialysis via central venous catheter

The business model took time to catch up to pharmacy’s potential, and community-based patient care leads the way

The sBLA was based on data from a clinical study assessing the pharmacokinetics of switching between adalimumab and adalimumab-bwwd for patients with moderate to severe plaque psoriasis.

Domvanalimab plus zimberelimab with chemotherapy demonstrated a positive overall response rate and 6-month progression free survival rate for patients with upper gastrointestinal cancers.

Preventative drug lists were associated with a modest increase in adherence to combination inhaled corticosteroid long-acting β2-agonists.

More individuals who used e-cigarettes have reported pulmonary diseases compared with those who never smoked, including asthma.

Regular usage of cannabis may increase the risk of heart failure, stroke, or heart attack, even after adjusting for other cardiovascular disease risk factors.

TAK-279 is an investigational oral allosteric tyrosine kinase 2 inhibitor for active psoriatic arthritis.

Investigators found that there was no association of dementia incidence in insulin use at 5 years after stopping metformin and an association at 0.07 years for HbA1C level at year 1.

In May 2023, the FDA approved brexpiprazole as the first and only drug to receive approval for treatment of agitation associated with Alzheimer Disease dementia.

Risk of atrial fibrillation with 1 of the independent predictors, including congestive heart failure and left atrial enlargement, resulted in greater than a 4-fold increased detection.

Pneumococcal serotype 3 was prevalent regardless of vaccination status, with the most common cases being in those with chronic lung disease.

In an article by The New England Journal of Medicine, the authors discuss how drug companies could delay the approval of new oncology drugs under the IRA, delaying patient care.

Without policies to reduce greenhouse gas emissions, the number of cardiovascular-related deaths due to extreme heat could even triple by mid-century.

Study also showed that 76% of individuals treated with lecanemab-irmb had no deterioration in the tau positron emission tomography (PET) subset.

Study finds that probable insomnia disorder was associated with physical health problems and difficulty with anger in veterans.

Arexvy shows efficacy in helping protect adults aged 50 to 59 years with an increased risk for respiratory syncytial virus lower respiratory tract disease.

Vosoritide is a daily injection for children with achondroplasia who have open epiphyses, given under the skin and administered by a caregiver.

BMS-986278 (Bristol Myers Squibb) is a potential first-in-class treatment for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis.

Patients with HIV who were resistant to treatment with lenacapavir (Sunlenca; Gilead Sciences Inc) were found to have inadequate adherence to optimized background regimen or did not have a fully active antiretroviral.

This marks the first time that experts have defined cardiovascular-kidney-metabolic syndrome, including the overlap of cardiovascular disease with kidney disease, type 2 diabetes, and obesity.

Among individuals who received systemic antibiotics within 8 weeks, 6 months, 12 months, and 24 months of receiving fecal microbiota, RBX2660 prevented recurrence.

The biosimilar landscape is growing, but the FDA should leverage analytical data to efficiently determine the quality of these products and propel them toward approval, according to a session at the Academy of Managed Care Pharmacy’s Nexus 2023 conference.

Approximately 96% physicians feel it is important to assess patients aged 60 years and older for cognitive impairment, but 48% of these patients have no had assessments from their physician.

The FDA is the only authority that can designate a biosimilar as interchangeable with its reference product, which requires that the product has similar clinical results for the same indication.